Markets

Radius Health's (RDUS) Q4 Loss Narrower than Expected - Tale of the Tape

Radius Health, Inc. ( RDUS ) is a development-stage biopharmaceutical company with a focus on the development of a potential treatment for advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers. This Cambridge, MA-based company has two candidates in its pipeline, namely, abaloparatide-SC (reduction of fractures in postmenopausal osteoporosis) and RAD1901 (treatment of postmenopausal women with advanced estrogen receptor positive and HER2-negative breast cancer).

With Radius Health not having any approved products in its portfolio, investor focus should remain on pipeline updates since a number of pipeline related activities are lined up for the rest of 2015.

Radius Health's earnings track record has been mixed with the company beating earnings estimates in one of the last two trailing quarters. The average negative earnings surprise stands at 125.76%. Loss estimates have widened for 2015.

Currently, Radius Health has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: Radius Health posted narrower-than-expected fourth quarter loss. Our consensus called for a loss of 59 cents per share, and the company reported a loss of 55 cents per share.

Revenues: The company did not generate any revenue in the fourth quarter as in the year-ago quarter.

Key Stats: Radius Health continues to progress with its pipeline. The company intends to submit regulatory applications for abaloparatide-SC in the U.S. and EU in the second half of 2015. Data from an ongoing six-month ACTIVExtend study on abaloparatide-SC is expected in the second quarter of this year. Additionally, Radius Health is enrolling patients in a phase I two-part, dose-escalation study on RAD1901 for the treatment of postmenopausal women with advanced estrogen receptor positive and HER2-negative breast cancer. Moreover, the company plans to initiate a phase IIb study on RAD1901 for the treatment of vasomotor symptoms in the second half of 2015.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

RADIUS HEALTH (RDUS): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

RDUS

Other Topics

Investing Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More